PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?

被引：60
作者：
Taieb, David [1 ]
Foletti, Jean-Marc [2 ]
Bardies, Manuel [3 ,4 ]
Rocchi, Palma [5 ]
Hicks, Rodney J. [6 ]
Haberkorn, Uwe [7 ,8 ]
机构：
[1] Aix Marseille Univ, La Timone Univ Hosp, Dept Nucl Med, CERIMED, Marseille, France
[2] Aix Marseille Univ, Hop Conception, AP HM, IFSTTAR,LBA,Chirurg Maxillofaciale, Marseille, France
[3] INSERM, UMR1037, CRCT, Toulouse, France
[4] Univ Toulouse III Paul Sabatier, CRCT, UMR1037, Toulouse, France
[5] Aix Marseille Univ, INSERM, CRCM, UMR1068, Marseille, France
[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[7] Univ Hosp Heidelberg, Dept Nucl Med, Heidelberg, Germany
[8] German Canc Res Ctr, Clin Cooperat Unit Nucl Med, Heidelberg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2018年 / 59卷 / 05期
关键词：
RESISTANT PROSTATE-CANCER; RADIOLIGAND THERAPY; DOSIMETRY;
D O I：
10.2967/jnumed.118.207993
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：747 / 748
页数：2
相关论文
共 10 条
[1]   Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 [J].
Afshar-Oromieh, Ali ;
Haberkorn, Uwe ;
Zechmann, Christian ;
Armor, Thomas ;
Mier, Walter ;
Spohn, Fabian ;
Debus, Nils ;
Holland-Letz, Tim ;
Babich, John ;
Kratochwil, Clemens .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) :950-959
[2]   The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer [J].
Afshar-Oromieh, Ali ;
Avtzi, Eleni ;
Giesel, Frederik L. ;
Holland-Letz, Tim ;
Linhart, Heinz G. ;
Eder, Matthias ;
Eisenhut, Michael ;
Boxler, Silvan ;
Hadaschik, Boris A. ;
Kratochwil, Clemens ;
Weichert, Wilko ;
Kopka, Klaus ;
Debus, Juergen ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :197-209
[3]   Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer [J].
Delker, Andreas ;
Fendler, Wolfgang Peter ;
Kratochwil, Clemens ;
Brunegraf, Anika ;
Gosewisch, Astrid ;
Gildehaus, Franz Josef ;
Tritschler, Stefan ;
Stief, Christian Georg ;
Kopka, Klaus ;
Haberkorn, Uwe ;
Bartenstein, Peter ;
Boening, Guido .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (01) :42-51
[4]   Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding [J].
Kratochwil, Clemens ;
Bruchertseifer, Frank ;
Rathke, Hendrik ;
Bronzel, Marcus ;
Apostolidis, Christos ;
Weichert, Wilko ;
Haberkorn, Uwe ;
Giesel, Frederik L. ;
Morgenstern, Alfred .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (10) :1624-1631
[5]   PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 [J].
Kratochwil, Clemens ;
Giesel, Frederik L. ;
Stefanova, Melsa ;
Benesova, Martina ;
Bronzel, Marcus ;
Afshar-Oromieh, Ali ;
Mier, Walter ;
Eder, Matthias ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (08) :1170-1176
[6]   PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer [J].
Kratochwil, Clemens ;
Giesel, Frederik L. ;
Leotta, Karin ;
Eder, Matthias ;
Hoppe-Tich, Torsten ;
Youssoufian, Hagop ;
Kopka, Klaus ;
Babich, John W. ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) :293-298
[7]   German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients [J].
Rahbar, Kambiz ;
Ahmadzadehfar, Hojjat ;
Kratochwil, Clemens ;
Haberkorn, Uwe ;
Schaefers, Michael ;
Essler, Markus ;
Baum, Richard P. ;
Kulkarni, Harshad R. ;
Schmidt, Matthias ;
Drzezga, Alexander ;
Bartenstein, Peter ;
Pfestroff, Andreas ;
Luster, Markus ;
Luetzen, Ulf ;
Marx, Marlies ;
Prasad, Vikas ;
Brenner, Winfried ;
Heinzel, Alexander ;
Mottaghy, Felix M. ;
Ruf, Juri ;
Meyer, Philipp Tobias ;
Heuschkel, Martin ;
Eveslage, Maria ;
Boegemann, Martin ;
Fendler, Wolfgang Peter ;
Krause, Bernd Joachim .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) :85-90
[8]   Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer [J].
Tagawa, Scott T. ;
Milowsky, Matthew I. ;
Morris, Michael ;
Vallabhajosula, Shankar ;
Christos, Paul ;
Akhtar, Naveed H. ;
Osborne, Joseph ;
Goldsmith, Stanley J. ;
Larson, Steve ;
Taskar, Neeta Pandit ;
Scher, Howard I. ;
Bander, Neil H. ;
Nanus, David M. .
CLINICAL CANCER RESEARCH, 2013, 19 (18) :5182-5191
[9]   Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer [J].
Yadav, Madhav P. ;
Ballal, Sanjana ;
Tripathi, Madhavi ;
Damle, Nishikant A. ;
Sahoo, Ranjit K. ;
Seth, Amlesh ;
Bal, Chandrasekhar .
NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (01) :91-98
[10]   Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy [J].
Zechmann, Christian M. ;
Afshar-Oromieh, Ali ;
Armor, Tom ;
Stubbs, James B. ;
Mier, Walter ;
Hadaschik, Boris ;
Joyal, John ;
Kopka, Klaus ;
Debus, Juergen ;
Babich, John W. ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (07) :1280-1292
1